Fate Therapeutics Inc (NASDAQ:FATE) currently has a daily average trading volume of 2.49M but it saw 4610425 shares traded in last market. With a market cap of 191.91M USD, the company’s current market price of $1.68 came falling about -10.37 while comparing to the previous closing price of $1.88. In past 52 weeks, the stock remained buoying in the range of price level as high as $8.83 and as low as $1.82. In the recent trading on the day, stock has struck highest price mark of $1.64 while lowest mark touched by it was $1.88.
Taking a look at 20-day trading activity of Fate Therapeutics Inc (FATE) gives us an average price of $2.3848, while its current price level is -80.92% below from 52-week high level whereas it is -7.42% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $2.5813 while that of 200 days or SMA-200 reads an average of $3.9959. A closer look into the stock’s movement over the week reveals that its volatility is standing at 12.91% during that period while stretching the period over a month that increases to 14.40%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 35.44 which implies that the stock is in neutral territory.
Piper Sandler upgraded its recommendation for the stock as a “Overweight” from “Neutral” on June 17, 2024 while assigning a price target range of $4-$6. Wells Fargo issued its recommendations for the stock as it resumed the price target for the stock is $6.
Over the week, FATE’s stock price is moving -22.71% down while it is -25.77% when we observe its performance for the past one month. Year-to-date it is -54.95% down and over the past year, the stock is showing a downside performance of -46.51%.
The company is expected to be releasing its next quarterly report in January, for which analysts forecasted an EPS of -0.43 while estimate for next year EPS is -1.59. In next quarter, company is expected to be making quarterly sales of $1.2M as analysts are expecting the sales for current fiscal year at $13.65M and seeing the company making $4.19M in sales next year. Moreover, analysts are in estimates of $1.57M for current-quarter revenue.
Currently, Fate Therapeutics Inc’s total number of outstanding shares is 113.88M with 2.17% of that held by the insiders while 102.85% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -39.22% and return on equity (ROE) at -46.59%. Stock’s beta reads 1.95. Stock has a price to book (P/B) ratio of 0.53 while price to sale or P/S ratio amounts to 14.27. Its return on asset (ROA) is -34.32% on average.
